We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?
Read MoreHide Full Article
Key Takeaways
Cytokinetics' aficamten improved cardiac structure and diastolic function in non-obstructive HCM.
Aficamten outperformed metoprolol across pre-trial treatment groups in patients with obstructive HCM.
Cytokinetics plans an nHCM filing in Q4 2026, potentially expanding aficamten's addressable market.
Cytokinetics, Incorporated (CYTK - Free Report) recently announced additional results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints in Adults with Non-Obstructive HCM) and MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) studies.
The results were presented in a Late Breaking Clinical Session at the European Society of Cardiology Congress 2026 in Munich, Germany.
Additional analyses of ACACIA-HCM and MAPLE-HCM elaborate on the primary results from each study and expand the evidence base supporting the potential use of aficamten across the spectrum of HCM.
We note that CYTK obtained FDA approval of aficamten under the brand name Myqorzo in December 2025 for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Strong initial uptake of the drug, along with Myqorzo’s expanding international presence, positions it as a meaningful commercial opportunity in the oHCM market.
CYTK is also looking to expand Myqorzo’s label.
More on CYTK’s ACACIA-HCM Study
ACACIA-HCM was a phase III, multi-center, randomized, double-blind, placebo-controlled study designed to evaluate the effect of aficamten compared to placebo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
Additional results from ACACIA-HCM demonstrate improvements in cardiac structure and diastolic function in patients with nHCM.
CYTK had earlier reported that ACACIA-HCM met both primary endpoints in symptomatic nHCM, showing statistically significant improvements in KCCQ Clinical Summary Score and maximal exercise performance (pVO2) versus placebo.
The additional ACACIA-HCM results suggest that aficamten’s benefits in nHCM may extend beyond improving exercise capacity and symptoms to reducing wall thickness and improving diastolic function. These findings provide further insight into how aficamten may benefit patients and highlight its potential as an important treatment option for nHCM, where no approved therapies currently exist.
Cytokinetics plans to submit a supplemental new drug application (sNDA) for aficamten in this indication in the fourth quarter of 2026. A potential approval in nHCM will expand the addressable market.
More on CYTK’s MAPLE-HCM Study
MAPLE-HCM was a phase III, multi-center, randomized, double-blind active-comparator clinical trial of aficamten compared to metoprolol in patients with symptomatic oHCM.
As previously reported, the primary results of MAPLE-HCM demonstrated superiority of aficamten to metoprolol on pVO2. This post-hoc analysis evaluated the effects of aficamten and metoprolol on the primary and key secondary endpoints based on pre-trial medical therapy.
The new analysis of MAPLE-HCM showed that aficamten outperformed metoprolol across pre-trial treatment groups in patients with oHCM.
The FDA had earlier accepted CYTK’s sNDA for MAPLE-HCM, a phase III study of aficamten as monotherapy compared with metoprolol as monotherapy in patients with oHCM. The regulatory body assigned a target action date of Nov. 14, 2026.
Competition for CYTK’s Myqorzo
Myqorzo operates within an evolving treatment landscape for oHCM. Its primary branded competitor is Camzyos, a cardiac myosin inhibitor marketed by Bristol Myers Squibb (BMY - Free Report) . In addition to this direct competition, Myqorzo faces established generic therapies, namely beta blockers and calcium channel blockers, which continue to serve as the first-line standard of care.
BMY obtained FDA approval for Camzyos in 2022 for the treatment of adults with symptomatic New York Heart Association class II-III obstructive HCM to improve functional capacity and symptoms.
The drug continues to gain traction in the targeted market, supported by growing demand and increased adoption among eligible patients.
The FDA accepted BMY’s supplemental new drug application seeking approval of Camzyos for the treatment of adolescents aged 12 to under 18 years with symptomatic oHCM.
A potential competitor for Cytokinetics is Edgewise Therapeutics, Inc. (EWTX - Free Report) , which is advancing a cardiovascular pipeline targeting HCM, heart failure, and other cardiovascular and cardiometabolic conditions.
EWTX’s lead candidate, EDG-7500, is a novel, oral, selective cardiac sarcomere modulator currently being studied in a multipart phase II study in patients with oHCM and nHCM, with a phase III program targeted to be launched in the fourth quarter of 2026.
EWTX’s pipeline also includes EDG-15400 for heart failure. The company expects to initiate a phase II study on EDG-15400 in participants with heart failure with preserved ejection fraction in the second half of 2026.
CYTK’s Price Movement, Valuation and Estimates
Cytokinetics’ shares have gained 12.4% year to date compared with the industry’s 8.7% growth.
Image Source: Zacks Investment Research
Going by the price/sales ratio, CYTK’s shares currently trade at 26.6X forward sales, higher than the industry’s average of 1.94X but lower than its mean of 49.08X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 loss per share has narrowed to $6 from $6.26 over the past 60 days and the same for 2027 loss has narrowed to $4.54 from $4.59 over the same period.
View the Zacks #1 Rank List
Image: Bigstock
Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?
Key Takeaways
Cytokinetics, Incorporated (CYTK - Free Report) recently announced additional results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints in Adults with Non-Obstructive HCM) and MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) studies.
The results were presented in a Late Breaking Clinical Session at the European Society of Cardiology Congress 2026 in Munich, Germany.
Additional analyses of ACACIA-HCM and MAPLE-HCM elaborate on the primary results from each study and expand the evidence base supporting the potential use of aficamten across the spectrum of HCM.
We note that CYTK obtained FDA approval of aficamten under the brand name Myqorzo in December 2025 for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Strong initial uptake of the drug, along with Myqorzo’s expanding international presence, positions it as a meaningful commercial opportunity in the oHCM market.
CYTK is also looking to expand Myqorzo’s label.
More on CYTK’s ACACIA-HCM Study
ACACIA-HCM was a phase III, multi-center, randomized, double-blind, placebo-controlled study designed to evaluate the effect of aficamten compared to placebo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
Additional results from ACACIA-HCM demonstrate improvements in cardiac structure and diastolic function in patients with nHCM.
CYTK had earlier reported that ACACIA-HCM met both primary endpoints in symptomatic nHCM, showing statistically significant improvements in KCCQ Clinical Summary Score and maximal exercise performance (pVO2) versus placebo.
The additional ACACIA-HCM results suggest that aficamten’s benefits in nHCM may extend beyond improving exercise capacity and symptoms to reducing wall thickness and improving diastolic function. These findings provide further insight into how aficamten may benefit patients and highlight its potential as an important treatment option for nHCM, where no approved therapies currently exist.
Cytokinetics plans to submit a supplemental new drug application (sNDA) for aficamten in this indication in the fourth quarter of 2026. A potential approval in nHCM will expand the addressable market.
More on CYTK’s MAPLE-HCM Study
MAPLE-HCM was a phase III, multi-center, randomized, double-blind active-comparator clinical trial of aficamten compared to metoprolol in patients with symptomatic oHCM.
As previously reported, the primary results of MAPLE-HCM demonstrated superiority of aficamten to metoprolol on pVO2. This post-hoc analysis evaluated the effects of aficamten and metoprolol on the primary and key secondary endpoints based on pre-trial medical therapy.
The new analysis of MAPLE-HCM showed that aficamten outperformed metoprolol across pre-trial treatment groups in patients with oHCM.
The FDA had earlier accepted CYTK’s sNDA for MAPLE-HCM, a phase III study of aficamten as monotherapy compared with metoprolol as monotherapy in patients with oHCM. The regulatory body assigned a target action date of Nov. 14, 2026.
Competition for CYTK’s Myqorzo
Myqorzo operates within an evolving treatment landscape for oHCM. Its primary branded competitor is Camzyos, a cardiac myosin inhibitor marketed by Bristol Myers Squibb (BMY - Free Report) . In addition to this direct competition, Myqorzo faces established generic therapies, namely beta blockers and calcium channel blockers, which continue to serve as the first-line standard of care.
BMY obtained FDA approval for Camzyos in 2022 for the treatment of adults with symptomatic New York Heart Association class II-III obstructive HCM to improve functional capacity and symptoms.
The drug continues to gain traction in the targeted market, supported by growing demand and increased adoption among eligible patients.
The FDA accepted BMY’s supplemental new drug application seeking approval of Camzyos for the treatment of adolescents aged 12 to under 18 years with symptomatic oHCM.
A potential competitor for Cytokinetics is Edgewise Therapeutics, Inc. (EWTX - Free Report) , which is advancing a cardiovascular pipeline targeting HCM, heart failure, and other cardiovascular and cardiometabolic conditions.
EWTX’s lead candidate, EDG-7500, is a novel, oral, selective cardiac sarcomere modulator currently being studied in a multipart phase II study in patients with oHCM and nHCM, with a phase III program targeted to be launched in the fourth quarter of 2026.
EWTX’s pipeline also includes EDG-15400 for heart failure. The company expects to initiate a phase II study on EDG-15400 in participants with heart failure with preserved ejection fraction in the second half of 2026.
CYTK’s Price Movement, Valuation and Estimates
Cytokinetics’ shares have gained 12.4% year to date compared with the industry’s 8.7% growth.
Image Source: Zacks Investment Research
Going by the price/sales ratio, CYTK’s shares currently trade at 26.6X forward sales, higher than the industry’s average of 1.94X but lower than its mean of 49.08X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 loss per share has narrowed to $6 from $6.26 over the past 60 days and the same for 2027 loss has narrowed to $4.54 from $4.59 over the same period.
Image Source: Zacks Investment Research
CYTK currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.